GenesisCare and Elekta Sign Strategic Partnership for More Than USD 100 Million

Thursday, March 31, 2016

Elekta announced today the formation of a multiyear strategic partnership with GenesisCare, the largest provider of radiotherapy in Australia. The deal, over eight years, is valued at more than USD 100 million. No part of the agreement will be booked in Q4 of this fiscal year.

The partnership includes the acquisition of solutions across Elekta’s portfolio, including Leksell Gamma Knife® Icon™ radiosurgery systems, Versa HD™ linear accelerators, brachytherapy systems, software as well as services. These products and solutions will be acquired by GenesisCare cancer treatment centers in Australia, the UK and new markets.

GenesisCare is also expected to order Elekta’s high-field (1.5 Tesla) MRI-guided linear accelerator (MR-linac*) when this new treatment technology is available in the market in 2017.

GenesisCare’s ambition is to transform health care and improve outcomes for cancer patients globally. A key enabler is the harmonization of its enterprise-wide practices and enhanced cancer management technology available for its highly skilled medical teams.

“We are proud to partner alongside GenesisCare and support their exciting vision,” says Tomas Puusepp, President and CEO of Elekta. “By choosing Elekta, GenesisCare will receive the most advanced and recognized cancer treatment solutions on the market. Both Leksell Gamma Knife and Versa HD are known for their extreme accuracy, efficiency and outstanding outcomes. We are looking forward to being GenesisCare’s partner as they expand into new markets.   GenesisCare Managing Director, Dan Collins, says: “Elekta is a natural partner for GenesisCare. We want all cancer patients to receive rapid access to high quality care.  Elekta helps us make this happen with their suite of technology solutions, global reach and commitment to innovation.

“The MR-linac is a game changer,” he adds. “We expect cancer patients, including those receiving treatment for prostate, breast and other cancers, to benefit from this innovation. Anything that improves the accuracy of treatment and provides a smoother patient experience should improve outcomes.”

Software systems included in the agreement comprise MOSAIQ® enterprise licensing, which provides a full-featured OIS to enable a completely optimized, automated workflow across their entire global enterprise – to fulfill the organization’s “Cancer Services of the Future” vision. The deal also includes METRIQ®, a fully integrated cancer registry for data collection and follow-up through reporting and analysis.


Source :